Publications
5674 Results
- Journal / Conference
- Blood 116:abst.#321; American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
Genetic polymorphisms in oxidative stress-related genes correlated with outcome following anthracycline-based therapy for aggressive B-cell non-hodgkins lymphomas
- Journal / Conference
- Blood 116:Abstract 1679; American Society of Hematology Annual Meeting; poster
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500
Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients
- Journal / Conference
- American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0605
A phase II study of lenalidomide for previously untreated deletion (del) 5q acute myeloid leukemia (AML) patients age 60 or older who are not candidates for remission induction chemotherapy (Southwest Oncology Group study S0605)
- Journal / Conference
- Blood 116:Abstract 589; ASH 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- E4494
R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large B-cell lymphoma (DLBCL) patients (pts): long-term follow-up of Intergroup E4494/C9793
- Journal / Conference
- Blood 116:abst.#415; American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- E2496
A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage hodgkin's lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
- Journal / Conference
- Blood 116:abst.#591; American Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0515
Phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and Rituximab (R-CHOP) plus bevacizumab for advanced stage diffuse large B-cell (DLBCL) NHL: Southwest Oncology Group study S0515
- Journal / Conference
- Blood 116:abst.#590; Society of Hematology 2010 Annual Meeting; oral
- Year
- 2010
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0433
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group protocol S0433
- Journal / Conference
- Blood 116:Abstract 6 (LBA-6); ASH late-breaking oral presentation
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0325
A randomized phase II trial of dasatinib 100 mg vs. imatinib 400 mg in newly diagnosed chronic phase (CML-CP): the S0325 intergroup trial
- Journal / Conference
- Blood 116:abst.#1038, 2010; American Society of Hematology Annual Mtg, poster
- Year
- 2010
- Research Committee(s)
- Leukemia
- Study Number(s)
- C9710